Dr. Heimberger on FGL2 as a Regulator of Tumor-Mediated Immune Suppression

Video

Amy B. Heimberger, MD, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma.

Amy B. Heimberger, MD, professor, Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma. Heimberger presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.

There is a lot of excitement surrounding immunotherapies and immune checkpoint inhibitors in glioblastoma, Heimberger says. It’s also understood that the mechanisms that the tumor uses for immunosuppression are very heterogenous. Because of this, Heimberger and her colleagues are researching pathways or mechanisms that deal with more than one mechanism of immune suppression.

FGL2 is a secreted protein that exploits multiple mechanisms of immune suppression to “stay behind” the detection of the immune system, Heimberger says. As FGL2 works on more than just immune checkpoints, Heimberger thinks that it could have a more profound impact for patients and could ultimately help more patients.

<<<

View more from the 2015 SNO Meeting

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Coral Olazagasti, MD
Samuel Rosner, MD
Balazs Halmos, MD